SolarEdge’s stock is shedding a quarter of its value as sales woes trump AI progress
The company faces challenges in Europe, which led to a weaker-than-expected revenue forecast.
Similar Posts
BRICS Is Rising, But How Powerful Is It? The Numbers Tell The Story
The broadly elliptical monument of Delhi, Bharat Mandapam, hosted the BRICS countries for two days last week, showcasing a blend of contemporary architecture, Indian heritage, and cuisines. About 28 leaders from 11 BRICS countries gathered to discuss bilateral trade, measures to eliminate trade barriers, and ways to strengthen economic relations. The most applauded point is…
Biotech Movers: Modular Medical Jumps, InnovAge Revenue Up 16%, Pyxis Data On Deck, Dogwood In Focus
(RTTNews) – With heightened trade tensions between the U.S. and Canada and rising oil prices weighing on investor sentiment, U.S. stocks came under pressure on Tuesday. Against this backdrop, the SPDR S&P Biotech ETF (XBI), a broad benchmark for the U.S. biotechnology sector, declined 1.15% during regular trading hours but edged 0.09% higher in overnight…
How to Choose the Right Credit Union for a HELOC
When you need financial flexibility, a home equity line of credit (HELOC) gives you access to potential funding for renovations, debt consolidation, or major expenses. If that’s the right solution for you, applying can be easier than you think. Here’s how to find a lender that makes borrowing simple and stress-free. What Is a HELOC…
9 Smart Home-Buying Tips From Real Estate Experts
There are right ways and wrong ways to buy a home. The latter of which will cost you a lot of unnecessary money, stress, and frustration. Use best practices, however — as offered by real estate experts below — and you’ll walk away a winner with a smile on your face and cash still in…
Kalshi Opens CFTC-Approved Gold And Silver Perpetual Futures
Kalshi has begun offering perpetual futures tied to gold and silver after the Commodity Futures Trading Commission (CFTC) cleared the listings, marking the prediction-market operator’s first move of this product type beyond digital assets. Trading in the new contracts opened Thursday on the company’s platform, following a filing submitted in July and regulatory review completed…
Argenx Just Landed Another Phase 3 Win — and Wall Street May Be Missing the Bigger Story
Argenx (ARGX +0.83%) already markets Vyvgart Hytrulo for treating generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), two rare chronic autoimmune diseases. It appears to be on track to add another approved indication for the drug. On Aug. 17, 2026, Argenx announced positive results from a Phase 3 clinical study evaluating Vyvgart Hytrulo…
